Inflammation is a significant component of several chronic diseases and its timely identification is critical for adequate treatment. The currently available methodologies are insufficient to meet this goal. We hypothesize that sensitive whole-body imaging of inflammation will enable early diagnosis and monitor therapy outcome. We have expertise to develop specific agents for in vivo imaging of inflammation. The work covers development of new radiopharmaceuticals and utilization of molecular imaging for medical applications from animal models to human studies. The host institute has state-of-art infrastructure to be at the forefront of international development in the field. The results are expected to provide new tools for molecular imaging and promote the translation of these tools into clinical use. We are now in an exciting phase as we have just taken a significant step beyond – moving to patient studies with VAP-1-targeted 68Ga-DOTA-Siglec-9, which we have developed by ourselves.

2022

2026